Seroatlas · Human Serome Atlas

IL17B

Interleukin-17B

Also known as: IL-17B, IL-20, IL17B_HUMAN, MGC138900, MGC138901, NIRF, ZCYTO7

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UHF5
Gene: IL17B
Ensembl: ENSG00000127743
Chromosome: 5
Canonical length: 180 aa
Protein class: Cancer-related genes, Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

The protein encoded by this gene is a T cell-derived cytokine that shares sequence similarity with IL17. This cytokine was reported to stimulate the release of TNF alpha (TNF) and IL1 beta (IL1B) from a monocytic cell line. Immunohistochemical analysis of several nerve tissues indicated that this cytokine is primarily localized to neuronal cell bodies. Alternative splicing results in multiple splice variants. [provided by RefSeq, Dec 2015]

Canonical amino-acid sequenceUniProt

180 residues, UniProt reviewed canonical sequence.

>Q9UHF5|IL17B
     1  MDWPHNLLFL LTISIFLGLG QPRSPKSKRK GQGRPGPLAP GPHQVPLDLV SRMKPYARME
    61  EYERNIEEMV AQLRNSSELA QRKCEVNLQL WMSNKRSLSP WGYSINHDPS RIPVDLPEAR
   121  CLCLGCVNPF TMQEDRSMVS VPVFSQVPVR RRLCPPPPRT GPCRQRAVME TIAVGCTCIF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IL17B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.46
Highest tissue expression: 11 nTPM

Expression across tissuesHPA

Tissue

blood vessel: 11 nTPM
cervix: 4.6 nTPM
testis: 3.6 nTPM
endometrium: 3.5 nTPM
colon: 2.9 nTPM
breast: 2.8 nTPM

Single-cell type

breast myoepithelial cells: 34 nCPM
vascular smooth muscle cells: 18 nCPM
peritubular myoid cells: 18 nCPM
tuft cells: 12 nCPM
salivary myoepithelial cells: 10 nCPM
smooth muscle cells: 9.6 nCPM

Immune cell

basophil: 1.2 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 1.5 nTPM
cerebral cortex: 0.8 nTPM
pons: 0.7 nTPM
medulla oblongata: 0.6 nTPM
hypothalamus: 0.5 nTPM
midbrain: 0.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.24
gnomAD pLI: 0.03
gnomAD missense Z: 0.52
DepMap mean gene effect: 0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

cytokine activity

Cellular components

extracellular space

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IL17B as an antibody target. Whether an autoantibody or antibody against IL17B could matter depends on whether native IL17B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IL17B is annotated as secreted, so native IL17B circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IL17B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...